Adicet Bio to report prula-cel Phase 1 lupus topline data in September 2026
ACET•Prula-cel lupus Phase 1 topline data due in September 2026
Adicet Bio completed the last patient visit for a planned Phase 1 analysis of prula-cel in systemic lupus erythematosus.
Results have not been presented; topline data are scheduled for September 2026, setting a near-term catalyst for the autoimmune program.
The readout is expected to clarify prula-cel’s early safety and efficacy profile, shaping next-step development decisions.
Pipeline updates for ADI-212 and an in vivo CAR-T candidate
Separately, the FDA cleared an IND for ADI-212 in metastatic castration-resistant prostate cancer; Phase 1 enrollment is expected in 4Q 2026.
Adicet also flagged a first in vivo CAR-T candidate for clinical entry in 2H 2027, extending its pipeline beyond ex vivo cell therapy.
